Breast Cancer Clinical Trials in Boston

Showing 41-60 of 598 trials

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

NCT06840483

This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent, unresectable, or metastatic breast cancer who have received prior therapy (see inclusion criteria below). The study will comprise of 2 cohorts. Cohort A will include participants with hormone receptor positive/ human epidermal growth factor receptor 2 negative \[HR+/HER2-\] breast cancer, whereas Cohort B will include participants with triple-negative breast cancer (TNBC).

Breast Cancer

BicycleTx Limited66 participantsStarted Mar 2025

Baltimore, Maryland, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +15 more locations

RECRUITINGPhase 1< 1 mile

A Study of XMT-1660 in Participants With Solid Tumors

NCT05377996

A Study of XMT-1660 in Solid Tumors

Triple Negative Breast CancerBreast CancerEndometrial Cancer+4 more

Mersana Therapeutics319 participantsStarted Aug 2022

Phoenix, Arizona, United States • Orange, California, United States • San Francisco, California, United States +23 more locations

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

A Study of XMT-1660 in Participants With Solid Tumors

Breast Cancer Trials in Other Cities

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

PF-07104091 as a Single Agent and in Combination Therapy

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Dance Study for Post-surgical Pain in Breast Cancer Survivors

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

GEN1047 for Solid Tumors - First in Human (FIH) Trial

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Other Conditions in Boston